⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4062497 | 0.97 | — | — | |
| SCHEMBL4059820 | 0.97 | — | — | |
| SCHEMBL1238338 | 0.97 | — | — | |
| SCHEMBL2225149 | 0.94 | — | — | |
| SCHEMBL9800820 | 0.75 | — | — | |
| SCHEMBL542161 | 0.73 | SLC6A1 (0.34) | — | |
| SCHEMBL641601 | 0.71 | TSHR (0.32) | — | |
| SCHEMBL10371841 | 0.71 | — | — | |
| SCHEMBL6538151 | 0.67 | — | — | |
| SCHEMBL4728246 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0853617-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | Novartis AG (CH) | 1998-07-22 | — | — | EP | claimed |
| WO-1997008155-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | claimed |
| EP-0475963-A4 | POLYMERIZABLE PYRROLIDONYL OXAZOLINE MONOMERS, HOMOPOLYMERS AND COPOLYMERS | — | 1992-06-24 | — | — | EP | claimed |
| EP-0475963-A1 | POLYMERIZABLE PYRROLIDONYL OXAZOLINE MONOMERS, HOMOPOLYMERS AND COPOLYMERS | ISP INVESTMENTS INC. (US) | 1992-03-25 | — | — | EP | claimed |
| WO-1990013544-A1 | POLYMERIZABLE PYRROLIDONYL OXAZOLINE MONOMERS, HOMOPOLYMERS AND COPOLYMERS | GAF CHEMICALS CORPORATION (US) | 1990-11-15 | — | — | WO | claimed |
| WO-2023235380-A1 | MACROLIDES FOR TREATING GENETIC DISEASES | ZIKANI THERAPEUTICS, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| CN-110769802-B | Solid powder cosmetic | 株式会社资生堂 | 2023-11-07 | — | — | CN | disclosed |
| CN-117015368-A | Spray out product | 株式会社大造 | 2023-11-07 | — | — | CN | disclosed |
| CN-110769803-B | Cosmetic containing titanium dioxide powder | 株式会社资生堂 | 2023-01-03 | — | — | CN | disclosed |
| US-11123269-B2 | Transparent solid composition | SHISEIDO COMPANY, LTD. (JP) | 2021-09-21 | — | — | US | disclosed |
| EP-3790859-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Temple University - Of The Commonwealth System of Higher Education (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20200179241-A1 | TRANSPARENT SOLID COMPOSITION | SHISEIDO COMPANY, LTD. (JP) | 2020-06-11 | — | — | US | disclosed |
| US-6080743-A | AS CHEMICAL INTERMEIDATES FOR PREPARING DRUGS | NOVARTIS AG (CH) | 2000-06-27 | — | — | US | disclosed |
| CN-1208603-A | Paraffin micro-dispersing composite and hair conditioning prepn. and finishing agent | SHISEIDO CO LTD (JP) | 1999-02-24 | — | — | CN | disclosed |
| EP-0853617-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | Novartis AG (CH) | 1998-07-22 | — | — | EP | disclosed |
| WO-1997008155-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
| US-4987210-A | COMPLEXING IODINE AND WATER-INSOLUBLE DRUGS TO MAKE THEM MORE SOLUBLE | GAF CHEMICALS CORPORATION (US) | 1991-01-22 | — | — | US | disclosed |
| US-4985521-A | COPOLYMERS, COMPLEXES WITH WATER INSOLUBLE MOLECULES | GAF CHEMICALS CORPORATION (US) | 1991-01-15 | — | — | US | disclosed |
| US-4946967-A | CHEMICAL INTERMEDIATES FOR HIGH MOLECULAR WEIGHT ACYCLIC ESTER OR AMIDE | GAF CHEMICALS CORPORATION (US) | 1990-08-07 | — | — | US | disclosed |
| WO-1990005131-A1 | POLYMERIZABLE DERIVATIVES OF 5-OXO-PYRROLINE CARBOXYLIC ACID, POLYMERS THEREOF AND METHODS OF PREPARATION | GAF CHEMICALS CORPORATION (US) | 1990-05-17 | — | — | WO | disclosed |